Anti-PD-1 for pretreated advanced anal carcinoma: which patients will benefit?
Mené sur 112 patients atteints d'un carcinome épidermoïde de l'anus de stade avancé (81 % de femmes), cet essai non randomisé de phase II évalue l'efficacité, du point de vue du taux de réponse objective, et la toxicité du pembrolizumab, après l'échec de traitements standard
In The Lancet Gastroenterology & Hepatology, Aurélien Marabelle and colleagues report the efficacy and safety of pembrolizumab in the anal squamous cell carcinomacohort of the non-randomised, multicohort, multicentre, phase 2 KEYNOTE-158 study.The results are promising, showing durable antitumour activity with pembrolizumabmonotherapy in a subset of patients, with objective responses observed in 12 (11%,95% CI 6 to 18) of 112 patients and a median duration of response not being reached(range 6·0+ to 33·9+ months) after a long median follow-up (34·7 months [IQR 32·5to 36·4]). The study also reports of an encouraging median overall survival of 11·9months (95% CI 9·1 to 14·9) and provides the first efficacy data according to PD-L1expression in this tumour type.
The Lancet Gastroenterology & Hepatology , commentaire, 2021